---
layout: default
title: Rosuvastatin
parent: Model Prediction Only (L5)
nav_order: 695
evidence_level: L5
indication_count: 10
---

# Rosuvastatin
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using no additional skill — this is a direct content-generation task with an explicit template already provided by the user; no coding, debugging, or brainstorming step applies.

# Rosuvastatin: From Hypercholesterolemia/Dyslipidemia to Cholesterol-Ester Transfer Protein Deficiency

## One-Sentence Summary

> Rosuvastatin is an HMG-CoA reductase inhibitor (statin); its original-indication licensing data is not on file in this Canadian evidence pack, though internationally it is an established treatment for hypercholesterolemia and mixed dyslipidemia.
> The TxGNN model's top-ranked prediction is **Cholesterol-Ester Transfer Protein (CETP) Deficiency** (score 99.54%),
> but this ranking is currently supported by **0 clinical trials** and only **2 case-report publications**, neither of which discusses CETP deficiency or rosuvastatin directly.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (drug currently not marketed in Canada, 0 licenses on file); internationally rosuvastatin is indicated for hypercholesterolemia and mixed dyslipidemia |
| Predicted New Indication | Cholesterol-Ester Transfer Protein (CETP) Deficiency |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action data for rosuvastatin is not available in this evidence pack (flagged as a High-severity gap, DG002). Based on information embedded in the TxGNN repurposing rationale, rosuvastatin is an HMG-CoA reductase inhibitor: it lowers hepatic de novo cholesterol synthesis and upregulates LDL-receptor expression, the same mechanism underlying its well-established use in hypercholesterolemia and dyslipidemia.

CETP deficiency, however, is a rare genetic disorder characterized by markedly elevated HDL-C and low LDL-C — a lipid phenotype essentially opposite to the one rosuvastatin is designed to correct. There is no established mechanistic rationale for why inhibiting hepatic cholesterol synthesis would address a primary defect in cholesteryl-ester transfer between lipoproteins, and the model's own rationale field explicitly flags this gap.

The high TxGNN score most likely reflects general graph-level proximity between statins and lipid-metabolism disease nodes rather than a disease-specific signal. The two supporting literature citations are case reports on unrelated conditions (Apo A-I deficiency and hepatic lipase deficiency) that mention CETP only in passing — they provide no direct evidence that rosuvastatin treats, or should be studied in, CETP deficiency. This is a case of a high embedding score without proportionate clinical support, consistent with the L5/Hold classification.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [21122686](https://pubmed.ncbi.nlm.nih.gov/21122686/) | 2010 | Case report | Journal of Clinical Lipidology | Describes an Iraqi Mandaean family with complete **Apo A-I deficiency** (a distinct HDL-metabolism disorder, not CETP deficiency); no rosuvastatin treatment data reported |
| [22798447](https://pubmed.ncbi.nlm.nih.gov/22798447/) | 2010 | Case report | BMJ Case Reports | First report measuring CETP activity/mass in a patient with **hepatic lipase deficiency**; provides background CETP biology but no data on rosuvastatin therapy or CETP deficiency itself |

## Canada Market Information

Rosuvastatin currently holds **no Health Canada market authorization** on file in this evidence pack — 0 DINs, market status "Not Marketed." No product licensing table can be generated until updated regulatory data becomes available.

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: key warnings, contraindications, and DDI data are all unresolved data gaps in this evidence pack — including a **Blocking**-severity gap, DG001, for the TFDA/Health Canada product monograph.)*

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted score is high, but supporting evidence is essentially absent — zero clinical trials, and the only two literature citations concern unrelated rare lipid disorders rather than CETP deficiency or rosuvastatin's use in it. A Blocking-severity data gap (missing product monograph) independently prevents advancement to Stage 1 safety screening regardless of efficacy evidence.

**To proceed, the following is needed:**
- Health Canada/TFDA product monograph (warnings, contraindications) — currently Blocking (DG001)
- DrugBank-verified mechanism of action data — currently High severity (DG002)
- Direct preclinical or clinical evidence specifically linking rosuvastatin to CETP-deficiency pathophysiology (current literature is off-target)
- Given the much stronger evidence for other candidates already present in this evidence pack — **familial hypercholesterolemia** (rank 2, L1, Proceed with Guardrails) and **hyperlipidemia** (rank 10, L1, Proceed with Guardrails) — consider prioritizing those for the next repurposing report instead of CETP deficiency
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

